Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Colorectal Neoplasms 8Neoplasms 2NSCLC 2Colonic Neoplasms 2Triple Negative Breast Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rectal Neoplasms 1Osteosarcoma 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Bone Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Malignancies 1

Interventions

Cyclophosphamide 10Irinotecan 8Melphalan 7Vincristine 6Temozolomide 6Doxorubicin 6Busulfan 6Topotecan 5Granulocyte Colony-Stimulating Factor 5Gemcitabine 5Ifosfamide 4Filgrastim 4Etoposide 4Albumin-Bound Paclitaxel 4Trabectedin 3Sirolimus 3Nivolumab 3130-nm albumin-bound paclitaxel 3pegfilgrastim 2olaparib 2fludarabine phosphate 2fludarabine 2eribulin 2cixutumumab 2abemaciclib 2X-Rays 2Radiotherapy, Intensity-Modulated 2Peripheral Blood Stem Cell Transplantation 2Magnetic Resonance Spectroscopy 2Granulocyte-Macrophage Colony-Stimulating Factor 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Sarcoma, Ewing × HMPL-013 × Clear all
NCT06202599 2024-01-17

Fruquintinib-based Treatment for Refractory Bone and Soft Tissue Sarcomas After Several Lines of TKIs' Resistance

Peking University People's Hospital

Completed
124 enrolled
Sarcoma

Bone Neoplasms, Neoplasms, Sarcoma, Sarcoma, Ewing, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡